oral delivery User types (acute injury, chronic pain, post-surgery, preventive maintenance) General Guidelines Daily use is key BPC-157 works best with consistent exposure over time Longer cycles (46+ weeks) yield better results than short bursts Injectable BPC-157 (subcutaneous or intramuscular) is superior for localized injury repair Oral capsules may be effective for gut healing and systemic inflammation , but less so for joint or tendon issues Acute Injury Protocol Use case : Recent muscle strain, tendon tweak, ligament sprain Duration : 46 weeks Dosage : 250500 mcg once or twice daily Injection : Subcutaneous, as close to the injury site as possible (without direct muscle penetration) Oral : 500 mcg twice daily (alternative if injection not viable) Tips : Pair with ice, compression, and gentle mobilization during week 1 Transition to light rehab work (banded movements, isometrics) by week 23 Maintain protein intake and consider stacking with Krill Oil and Greens + Reds for inflammation control Chronic Injury or Joint Pain Protocol Use case : Tendonitis, joint instability, degenerative wear and tear Duration : 68 weeks minimum Dosage : 500 mcg twice daily Injection : SubQ near affected joint (e.g., patellar tendon, shoulder capsule) Optional Stack : TB-500 for systemic healing, ZMT to support recovery sleep Tips : Combine with soft tissue therapy (e.g., ART, dry needling) Train with joint-friendly movements: controlled eccentrics, banded work, low-impact conditioning Follow a nutrition protocol via The Swole Kitchen to reduce inflammation and support collagen synthesis Post-Surgical Repair Protocol Use case : ACL, meniscus, rotator cuff, labrum, tendon reattachment Duration : 812 weeks Dosage : 500750 mcg/day (split into 2 doses) Injection : SubQ or shallow IM near surgical site (with surgeon clearance) Add-ons : DHEA (100 mg/day) to support anabolic environment Collagen peptides or bone broth ZMT to support quality sleep for tissue remodeling Recovery after surgery involves extensive tissue remodeling and angiogenesis
pylori therapy is recommended for cancer and ulcer patients and for patients with some precancer symptoms
Nadeem Anjam, Y., Shahid, I., Emadifar, H., Arif Cheema, S
It significantly represses CHAC1 promoter activity without binding DNA directly
Treated rats developed white nodules at the injection sites
